Sat Oct 25 14:58:07 SGT 2014  
SINGAPORE
VACCINE™
    Vaccine, Singapore (SG)

Vaccine, Singapore (SG)

Summary

Vaccine, Singapore (SG) @singaporevaccine_com: vaccine jab/shot/injection schedule, to vaccinate against the infection, to immunise against infectious disease, Singapore. Private and confidential service. Definitions, references, and latest news.

Description

Vaccine types available for vaccination / immunisation (uk) / immunization (us) :

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Live attenuated
MMR vaccine ≥12m 1 $70/=
Measles virus Measles
Mumps virus Mumps
Rubella virus Rubella
Varilrix™ Varicella zoster virus
HHV-3
Varicella Chickenpox 12m-12y 1 $121/=
≥13y 2 6-10w interval
Zostavax™ Herpes zoster Shingles ≥50y 1 $400/=
Stamaril® Yellow fever virus Yellow fever 9m-59y 1 10 yearly $250/=
Inactivated / Whole / Viral & Bacterial
Rabipur® Rabies virus Rabies any 3 d 0, 7, & 21 or 28 $call/=
Ixiaro® Japanese encephalitis virus Japanese encephalitis ≥17y 2 2nd: 28d after 1st $386/=
1 Booster: 12-24m after 2nd
Dukoral® Vibrio cholerae Cholera 2-6y 3 1-6w interval $113/=
1 Booster: 6m after 3rd
≥6y 2 1-6w interval
1 Booster: 2y after 2nd
Inactivated / Fractional / Protein
Intanza™ Influenza virus Influenza 18-59y 1 1 yearly $30/=
Fluarix™ Influenza virus Influenza 6-36m ½ 1 yearly $30/=
>3y 1
Tetavax Clostridium tetani Tetanus adults 3 1-2m interval
3rd @ 6-12m
after 2nd
$30/=
booster 1 10 yearly
Boostrix® ≥4y 1 <10 yearly $70/=
Corynebacterium diphtheriae Diphtheria
Clostridium tetani Tetanus
Bordetella pertussis Pertussis
Whooping cough
Inactivated / Fractional / Polysaccharide / Pure
Typhim Vi® Salmonella typhi Typhoid fever >5y 1 3 yearly $48/=
Mencevax® ACWY Neisseria meningitidis
types A, C, W-135
and Y
Meningococcal meningitis >2y 1 $80/=
Inactivated / Fractional / Polysaccharide / Conjugate
Menactra® Neisseria meningitidis
types A, C, W-135
and Y
Meningococcal meningitis 2-55y 1 $220/=
Prevenar 13® (SG) /
Prevnar 13® (US)
Streptococcus pneumoniae
types 1, 3, 4, 5,
6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, 23F
Pneumococcal infection 6w-6m 4 1m interval
4th @ 12-15m
$274/=
7-11m 2 1m interval
12-23m 2 2m interval
2-5y 1
≥50y 1

If the clinic attendance is just for vaccination alone, no additional consultation fees are charged.

Testing for immunity against the following is available:

Virus Antibody Test Price
Varicella zoster virus Varicella Zoster IgG Antibody $44/=
Measles virus Measles IgG Antibody $90/=
Rubella virus Rubella IgG Antibody $24/=
Hepatitis A virus Hepatitis A IgG Antibody $30/=
Hepatitis B virus Hepatitis B surface Antibody $10/=

Other vaccines not stocked

References

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Vaccine, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

References


Latest News

Vaccine promotion messages may not encourage vaccination
Sat, 25 Oct 2014 03:12:38 +0100 | The Journal of Pediatrics
Nyhan B, Reifler J, Richey S, Freed GL. Effective messages in vaccine promotion: a randomized trial. Pediatrics 2014;133:e835-42. Among parents with young children, what is the efficacy of vaccine-promotion-type messages, compared with controls, in enhancing intention to vaccinate? (Source: The Journal of Pediatrics)

[Comment] Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine
Sat, 25 Oct 2014 00:00:00 +0100 | LANCET
In The Lancet, Jacob John and colleagues report results from a randomised trial of 450 children from Vellore, India, aged 1–4 years that assessed the effects of giving a dose of inactivated poliovirus vaccine (IPV) to children previously immunised with five or more doses of oral poliovirus vaccine (OPV) at least 6 months before the study. The results confirm that an extra dose of IPV in this population increases serum antibodies. The study goes further to show that the IPV dose boosts individual intestinal immunity in OPV-vaccinated children, at least for a short period of time. (Source: LANCET)

[Comment] Pertussis vaccine in pregnancy—first dose for every infant?
Sat, 25 Oct 2014 00:00:00 +0100 | LANCET
The potential for whole-cell pertussis vaccination in pregnancy to reduce high-mortality early infant disease was first shown almost 75 years ago. Although interest was rekindled by the advent of acellular pertussis vaccines in the 1980s, the first recommendation for routine pertussis vaccination in pregnancy was not given until 2011. Uptake of this recommendation in the USA has been slow, and empirical evidence that pertussis vaccination in pregnancy prevents early infant disease is lacking. (Source: LANCET)

[Articles] Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial
Sat, 25 Oct 2014 00:00:00 +0100 | LANCET
The substantial boost in intestinal immunity conferred by a supplementary dose of IPV given to children younger than 5 years who had previously received OPV shows a potential role for this vaccine in immunisation activities to accelerate eradication and prevent outbreaks of poliomyelitis. (Source: LANCET)

[Articles] Effectiveness of maternal pertussis vaccination in England: an observational study
Sat, 25 Oct 2014 00:00:00 +0100 | LANCET
Our assessment of the programme of pertussis vaccination in pregnancy in England is consistent with high vaccine effectiveness. This effectiveness probably results from protection of infants by both passive antibodies and reduced maternal exposure, and will provide valuable information to international policy makers. (Source: LANCET)

Watch TIME’s Jeffery Kluger Discuss How to Eradicate Polio
Fri, 24 Oct 2014 22:29:51 +0100 | TIME.com: Top Science and Health Stories
Since the development of a Polio vaccine in the 1950s, the number of cases of the devastating disease has been reduced by 99 percent. But despite a cure, people in three countries still suffer from the disease. Now, foundations like the World Health Organization, Centers for Disease Control and Prevention and UNICEF have teamed up to eradicate the disease.

vaccine_development.11.aspx target=_blank rel="nofollow">Novel immunotherapy vaccine development
Fri, 24 Oct 2014 20:48:51 +0100 | Current Opinion in Allergy and Clinical Immunology
Purpose of reviewAllergen-specific immunotherapy is the only curative treatment for allergic diseases. In spite of the great progress in both vaccine development and the methods of allergen immunotherapy (AIT) in recent years, several key problems related to limited efficacy, side-effects, low patient adherence and the relatively high costs due to the long duration (3–5 years) remain to be solved. The current approaches aiming at optimization of AIT are reviewed, including both conceptual studies in experimental models and proof-of-concept – as well as large, multicenter clinical studies.

WHO says Ebola vaccine plans accelerating as trials advance
Fri, 24 Oct 2014 16:38:21 +0100 | Reuters: Health
GENEVA/LONDON (Reuters) - Trials of Ebola vaccines could begin in West Africa in December, a month earlier than expected, and hundreds of thousands of doses should be available for use by the middle of next year, the World Health Organization said on Friday. (Source: Reuters: Health)

​WHO speeding up development of Ebola vaccine
Fri, 24 Oct 2014 16:38:17 +0100 | Health News: CBSNews.com
Says millions of vaccine doses could be ready by mid-2015; at least five experimental drugs are expected to join others already undergoing clinical trials (Source: Health News: CBSNews.com)

vaccines/ target=_blank rel="nofollow">J&J and GSK Collaborate on Producing Millions of Ebola Vaccines
Fri, 24 Oct 2014 16:37:00 +0100 | PharmaManufacturing.com
Johnson & Johnson has made a commitment of up to $200 million to accelerate the production of an Ebola vaccine program (Source: PharmaManufacturing.com)